Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 100 |
| Active Pipeline (Recruiting Now) | 45 (28) |
| Completed vs Stopped Early | 25 / 30 (30.0%) |
| Median Closed Actual Enrollment | 36 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| University of Alabama at Birmingham | Birmingham, AL | 57 |
| Mayo Clinic Rochester | Rochester, MN | 6 |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | 6 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05026749 | Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children | Phase III | RECRUITING |
| NCT06188741 | Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase II | RECRUITING |
| NCT04692493 | RA-PRO PRAGMATIC TRIAL | Phase III | RECRUITING |
| NCT05231629 | Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | Phase II | ACTIVE NOT RECRUITING |
| NCT05143840 | Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the University of Alabama at Birmingham Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.